07:49 AM EDT, 08/29/2025 (MT Newswires) -- iRhythm Technologies ( IRTC ) said Friday that a clinical trial demonstrated that its Zio long-term continuous monitoring device led to increased atrial fibrillation detection and a shorter time to diagnosis.

The trial was designed to determine whether the Zio device could improve atrial fibrillation detection in people aged 65 years and older who are at moderate to high risk of stroke, compared to usual care over 2.5 years of follow-up, the company said.

The results of the study were presented at the European Society of Cardiology Congress 2025 and were published in the Journal of the American Medical Association.